Get startedLog in
    Picture of Xeris Biopharma Holdings logo

    XERS — Xeris Biopharma Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    All News

    Brief: Xeris Expects To End 2022 With Over $120 Mln In Cash, Cash Equivalents & Short-Term Investments

    Picture of Xeris Biopharma Holdings logoXeris Biopharma Holdings
    05/01/2023 12:15
    Jan 5 (Reuters) - Xeris Biopharma Holdings Inc  XERS.O :
    * XERIS - EXPECTS TO END 2022 WITH OVER $120M IN CASH,CASH
EQUIVALENTS & SHORT-TERM INVESTMENTS & TOP OF NET PRODUCT
REVENUE GUIDANCE OF $105 MILLION-$110 MILLION

Source text for Eikon:  ID:nBw2JX8Pma 
Further company coverage:  XERS.O 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Xeris Biopharma Holdings

    See all news